198 related articles for article (PubMed ID: 14640551)
1. 1,2-benzisoxazole phosphorodiamidates as novel anticancer prodrugs requiring bioreductive activation.
Jain M; Kwon CH
J Med Chem; 2003 Dec; 46(25):5428-36. PubMed ID: 14640551
[TBL] [Abstract][Full Text] [Related]
2. Denitrosation of the anti-cancer drug 1,3-bis(2-chloroethyl)-1-nitrosourea catalyzed by microsomal glutathione S-transferase and cytochrome P450 monooxygenases.
Weber GF; Waxman DJ
Arch Biochem Biophys; 1993 Dec; 307(2):369-78. PubMed ID: 8274024
[TBL] [Abstract][Full Text] [Related]
3. Substituent effect on the reductive N-dearylation of 3-(indol-1-yl)-1,2-benzisoxazoles by rat liver microsomes.
Tschirret-Guth RA; Wood HB
Drug Metab Dispos; 2003 Aug; 31(8):999-1004. PubMed ID: 12867488
[TBL] [Abstract][Full Text] [Related]
4. Nitroaryl phosphoramides as novel prodrugs for E. coli nitroreductase activation in enzyme prodrug therapy.
Hu L; Yu C; Jiang Y; Han J; Li Z; Browne P; Race PR; Knox RJ; Searle PF; Hyde EI
J Med Chem; 2003 Nov; 46(23):4818-21. PubMed ID: 14584930
[TBL] [Abstract][Full Text] [Related]
5. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
Chen CS; Jounaidi Y; Waxman DJ
Drug Metab Dispos; 2005 Sep; 33(9):1261-7. PubMed ID: 15919850
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
[TBL] [Abstract][Full Text] [Related]
7. Formation of reductive metabolite, 2-sulfamoylacetylphenol, from zonisamide in rat liver microsomes.
Nakasa H; Komiya M; Ohmori S; Kitada M; Rikihisa T; Kanakubo Y
Res Commun Chem Pathol Pharmacol; 1992 Jul; 77(1):31-41. PubMed ID: 1439179
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of novel androgen-linked phosphoramide mustard prodrugs and growth-inhibitory activity in human breast cancer cells.
Roth T; Tang W; Eisenbrand G
Anticancer Drug Des; 1995 Dec; 10(8):655-66. PubMed ID: 8595124
[TBL] [Abstract][Full Text] [Related]
9. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ
J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097
[TBL] [Abstract][Full Text] [Related]
10. Reduction of 3'-azido-2',3'-dideoxynucleosides to their 3'-amino metabolite is mediated by cytochrome P-450 and NADPH-cytochrome P-450 reductase in rat liver microsomes.
Cretton EM; Sommadossi JP
Drug Metab Dispos; 1993; 21(5):946-50. PubMed ID: 7902260
[TBL] [Abstract][Full Text] [Related]
11. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
[TBL] [Abstract][Full Text] [Related]
12. Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N',N''-triethylenethiophosphoramide.
Teicher BA; Waxman DJ; Holden SA; Wang YY; Clarke L; Alvarez Sotomayor E; Jones SM; Frei E
Cancer Res; 1989 Sep; 49(18):4996-5001. PubMed ID: 2504483
[TBL] [Abstract][Full Text] [Related]
13. Influence of mustard group structure on pathways of in vitro metabolism of anticancer N-(2-hydroxyethyl)-3,5-dinitrobenzamide 2-mustard prodrugs.
Helsby NA; Goldthorpe MA; Tang MH; Atwell GJ; Smith EM; Wilson WR; Tingle MD
Drug Metab Dispos; 2008 Feb; 36(2):353-60. PubMed ID: 17998296
[TBL] [Abstract][Full Text] [Related]
14. Preactivated oxazaphosphorines designed for isophosphoramide mustard delivery as bulk form or nanoassemblies: synthesis and proof of concept.
Skarbek C; Lesueur LL; Chapuis H; Deroussent A; Pioche Durieu C; Daville A; Caron J; Rivard M; Martens T; Bertrand JR; Le Cam E; Vassal G; Couvreur P; Desmaele D; Paci A
J Med Chem; 2015 Jan; 58(2):705-17. PubMed ID: 25494842
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and anti-cancer activity of 2,6-disubstituted N-methylpiperidine derivatives and their N-oxides.
Henderson ND; Plumb JA; Robins DJ; Workman P
Anticancer Drug Des; 1996 Sep; 11(6):421-38. PubMed ID: 8836108
[TBL] [Abstract][Full Text] [Related]
16. Nitroimidazole-based "extruded mustards' designed as reductively activated hypoxia-selective cytotoxins.
Hay MP; Denny WA; Wilson WR
Anticancer Drug Des; 1996 Jul; 11(5):383-402. PubMed ID: 8765531
[TBL] [Abstract][Full Text] [Related]
17. Sulfonyl-containing aldophosphamide analogues as novel anticancer prodrugs targeted against cyclophosphamide-resistant tumor cell lines.
Jain M; Fan J; Baturay NZ; Kwon CH
J Med Chem; 2004 Jul; 47(15):3843-52. PubMed ID: 15239662
[TBL] [Abstract][Full Text] [Related]
18. Oxidative and reductive metabolism of tris(p-carboxyltetrathiaaryl)methyl radicals by liver microsomes.
Decroos C; Li Y; Bertho G; Frapart Y; Mansuy D; Boucher JL
Chem Res Toxicol; 2009 Jul; 22(7):1342-50. PubMed ID: 19545126
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.
Lengler J; Omann M; Düvier D; Holzmüller H; Gregor W; Salmons B; Günzburg WH; Renner M
Biochem Pharmacol; 2006 Sep; 72(7):893-901. PubMed ID: 16887103
[TBL] [Abstract][Full Text] [Related]
20. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation.
Helsby NA; Wheeler SJ; Pruijn FB; Palmer BD; Yang S; Denny WA; Wilson WR
Chem Res Toxicol; 2003 Apr; 16(4):469-78. PubMed ID: 12703963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
